FDA offers quick review for Shire's prospective blockbuster lanadelumab; Big Pharma loves big buybacks
→ The FDA is helping Shire $SHPG hustle along its application for lanadelumab, which the big biotech believes can peak out at $2 billion in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
